Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1993 Mar;48(3):227–232. doi: 10.1136/thx.48.3.227

Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.

S E McKay 1, C A Howie 1, A H Thomson 1, B Whiting 1, G J Addis 1
PMCID: PMC464358  PMID: 8497820

Abstract

BACKGROUND: It is still not certain whether it is worth using theophylline in addition to inhaled bronchodilators and corticosteroids to treat obstructive airways disease. This trial was designed to test whether the addition of prescribed theophylline in doses sufficient for sustained optimal steady state plasma concentrations would produce any detectable additional advantage in spirometric or functional variables in these handicapped patients. METHODS: A randomised, double blind, placebo controlled, crossover study of added theophylline treatment was aimed at steady state plasma concentrations of 10 and 17 mg/l, the dose being calculated individually by Bayesian parameter estimation and maintained for six weeks along with the patient's previously prescribed bronchodilators and steroids. Of 20 patients sequentially recruited, 15 provided data that could be analysed. All had chronic obstructive lung disease with a mean forced expiratory volume in the first second (FEV1) up to about 30% of the predicted value and gave no history of being treated with theophylline. The protocol included spirometry, whole body plethysmography, and treadmill exercise. Measurements also included steady state plasma theophylline concentrations and trapped gas volume. Quality of life was assessed by an established questionnaire method covering breathlessness in everyday activities, fatigue, emotional function, and control over the disease. RESULTS: Both target plasma concentrations were achieved. Improvements in peak flow (PEF; mean 20%), trapped gas volumes (38%), two stage vital capacity (15%), distances walked (48%), breathlessness in everyday activities (32%), and fatigue (18%) were found at the higher plasma concentration only. FEV1, forced vital capacity (FVC), emotional function, and control did not change. CONCLUSION: Theophylline treatment with sustained steady state concentrations about 17 mg/l provides worthwhile objective and subjective further benefits for patients handicapped by chronic obstructive lung disease when it is added to bronchodilators and corticosteroids.

Full text

PDF
227

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addis G. J. Theophylline in the management of airflow obstruction. 1. Much evidence suggests that theophylline is valuable. BMJ. 1990 Apr 7;300(6729):928–929. doi: 10.1136/bmj.300.6729.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alexander M. R., Dull W. L., Kasik J. E. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study. JAMA. 1980 Nov 21;244(20):2286–2290. [PubMed] [Google Scholar]
  3. Beaumont A., Cockcroft A., Guz A. A self paced treadmill walking test for breathless patients. Thorax. 1985 Jun;40(6):459–464. doi: 10.1136/thx.40.6.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chrystyn H., Mulley B. A., Peake M. D. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ. 1988 Dec 10;297(6662):1506–1510. doi: 10.1136/bmj.297.6662.1506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clark C. J., Boyd G. Combination of aminophylline (Phyllocontin Continus tablets) and salbutamol in the management of chronic obstructive airways disease. Br J Clin Pharmacol. 1980 Apr;9(4):359–364. doi: 10.1111/j.1365-2125.1980.tb01062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dullinger D., Kronenberg R., Niewoehner D. E. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest. 1986 Feb;89(2):171–173. doi: 10.1378/chest.89.2.171. [DOI] [PubMed] [Google Scholar]
  7. Eaton M. L., MacDonald F. M., Church T. R., Niewoehner D. E. Effects of theophylline on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Chest. 1982 Nov;82(5):538–542. doi: 10.1378/chest.82.5.538. [DOI] [PubMed] [Google Scholar]
  8. Evans W. V. Plasma theophylline concentrations, six minute walking distances, and breathlessness in patients with chronic airflow obstruction. Br Med J (Clin Res Ed) 1984 Dec 15;289(6459):1649–1651. doi: 10.1136/bmj.289.6459.1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Greening A. P., Baillie E., Gribbin H. R., Pride N. B. Sustained release oral aminophylline in patients with airflow obstruction. Thorax. 1981 Apr;36(4):303–307. doi: 10.1136/thx.36.4.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Guyatt G. H., Berman L. B., Townsend M., Pugsley S. O., Chambers L. W. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct;42(10):773–778. doi: 10.1136/thx.42.10.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Guyatt G. H., Townsend M., Keller J., Singer J., Nogradi S. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med. 1989 Jul;83(4):293–297. doi: 10.1016/s0954-6111(89)80199-4. [DOI] [PubMed] [Google Scholar]
  12. Guyatt G. H., Townsend M., Pugsley S. O., Keller J. L., Short H. D., Taylor D. W., Newhouse M. T. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis. 1987 May;135(5):1069–1074. doi: 10.1164/arrd.1987.135.5.1069. [DOI] [PubMed] [Google Scholar]
  13. Hill N. S. The use of theophylline in 'irreversible' chronic obstructive pulmonary disease. An update. Arch Intern Med. 1988 Dec;148(12):2579–2584. [PubMed] [Google Scholar]
  14. Jenkins P. F., White J. P., Jariwalla A. J., Anderson G., Campbell I. A. A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis. Br J Dis Chest. 1982 Jan;76(1):57–60. [PubMed] [Google Scholar]
  15. Johnston I. D. Theophylline in the management of airflow obstruction. 2. Difficult drugs to use, few clinical indications. BMJ. 1990 Apr 7;300(6729):929–931. doi: 10.1136/bmj.300.6729.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kelman A. W., Whiting B., Bryson S. M. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol. 1982 Aug;14(2):247–256. doi: 10.1111/j.1365-2125.1982.tb01969.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Knox A. J., Morrison J. F., Muers M. F. Reproducibility of walking test results in chronic obstructive airways disease. Thorax. 1988 May;43(5):388–392. doi: 10.1136/thx.43.5.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kongragunta V. R., Druz W. S., Sharp J. T. Dyspnea and diaphragmatic fatigue in patients with chronic obstructive pulmonary disease. Responses to theophylline. Am Rev Respir Dis. 1988 Mar;137(3):662–667. doi: 10.1164/ajrccm/137.3.662. [DOI] [PubMed] [Google Scholar]
  19. Leitch A. G., Morgan A., Ellis D. A., Bell G., Haslett C., McHardy G. J. Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis. Thorax. 1981 Oct;36(10):787–789. doi: 10.1136/thx.36.10.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mahler D. A., Matthay R. A., Snyder P. E., Wells C. K., Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis. 1985 Jan;131(1):22–25. doi: 10.1164/arrd.1985.131.1.22. [DOI] [PubMed] [Google Scholar]
  21. Mahler D. A., Weinberg D. H., Wells C. K., Feinstein A. R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984 Jun;85(6):751–758. doi: 10.1378/chest.85.6.751. [DOI] [PubMed] [Google Scholar]
  22. Marvin P. M., Baker B. J., Dutt A. K., Murphy M. L., Bone R. C. Physiologic effects of oral bronchodilators during rest and exercise in chronic obstructive pulmonary disease. Chest. 1983 Dec;84(6):684–689. doi: 10.1378/chest.84.6.684. [DOI] [PubMed] [Google Scholar]
  23. McGavin C. R., Gupta S. P., McHardy G. J. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J. 1976 Apr 3;1(6013):822–823. doi: 10.1136/bmj.1.6013.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Morgan A. D., Peck D. F., Buchanan D. R., McHardy G. J. Effect of attitudes and beliefs on exercise tolerance in chronic bronchitis. Br Med J (Clin Res Ed) 1983 Jan 15;286(6360):171–173. doi: 10.1136/bmj.286.6360.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Murciano D., Auclair M. H., Pariente R., Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med. 1989 Jun 8;320(23):1521–1525. doi: 10.1056/NEJM198906083202304. [DOI] [PubMed] [Google Scholar]
  26. Pineda H., Haas F., Axen K., Haas A. Accuracy of pulmonary function tests in predicting exercise tolerance in chronic obstructive pulmonary disease. Chest. 1984 Oct;86(4):564–567. doi: 10.1378/chest.86.4.564. [DOI] [PubMed] [Google Scholar]
  27. Roberts J. A., Pugh J. R., Thomson N. C. A new adaptable computerized system for the measurement of specific airways conductance. Br J Dis Chest. 1986 Jul;80(3):218–228. doi: 10.1016/0007-0971(86)90056-2. [DOI] [PubMed] [Google Scholar]
  28. Shohat B., Volovitz B., Varsano I. Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin Allergy. 1983 Sep;13(5):487–493. doi: 10.1111/j.1365-2222.1983.tb02626.x. [DOI] [PubMed] [Google Scholar]
  29. Taylor D. R., Buick B., Kinney C., Lowry R. C., McDevitt D. G. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis. 1985 May;131(5):747–751. doi: 10.1164/arrd.1985.131.5.747. [DOI] [PubMed] [Google Scholar]
  30. Torphy T. J., Undem B. J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 1991 Jul;46(7):512–523. doi: 10.1136/thx.46.7.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ullah M. I., Cuddihy V., Saunders K. B., Addis G. J. How many blows really make an FEV1, FVC, or PEFR? Thorax. 1983 Feb;38(2):113–118. doi: 10.1136/thx.38.2.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vereen L. E., Kinasewitz G. T., George R. B. Effect of aminophylline on exercise performance in patients with irreversible airway obstruction. Arch Intern Med. 1986 Jul;146(7):1349–1351. [PubMed] [Google Scholar]
  33. Whiting B., Kelman A. W., Barclay J., Addis G. J. Modelling theophylline response in individual patients with chronic bronchitis. Br J Clin Pharmacol. 1981 Oct;12(4):481–487. doi: 10.1111/j.1365-2125.1981.tb01254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wolkove N., Dajczman E., Colacone A., Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest. 1989 Dec;96(6):1247–1251. doi: 10.1378/chest.96.6.1247. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES